What is BRI’s Diabetes Biorepository?
The Diabetes Biorepository is a confidential list of people with type type 1 diabetes (T1D) who donate samples and provide health information for scientific research. This library of samples and information helps our scientists study how and why T1D starts and make progress toward prevention and better treatments.
Participate in Diabetes Research
We invite individuals with T1D to participate in this research to help us improve our understanding of diabetes and immune-mediated diseases.
We are also looking for family members of all ages who do not have type Type 1 diabetes or another immune-mediated or autoimmune disease, to join our Healthy Volunteer Registry.
Participating in research typically involves a 45-60 -minute visit to BRI in downtown Seattle. Our team will collect a blood sample and ask questions about your personal and family medical history. All samples and information are kept confidential. Learn more: Biorepository FAQ
Learn more about type 1 diabetes.
Are you living with or at risk of developing T1D?
Sandra Lord, MD
Labs Studying Type 1 Diabetes
Collaborate with us
Science in Seattle: A Promising New Approach to Stopping Type 1 DiabetesRead more ➡
Exploring autoimmunity's regulatory rootsRead more ➡
Autoimmunity in Down Syndrome Arises From Rapid Immune AgingRead more ➡
Teplizumab FAQ: Your Questions Answered About New Therapy to Delay T1D
Scientists at the Benaroya Research Institute (BRI) and TrialNet, a global type 1 diabetes (T1D) research consortium, have spent decades working to answer a bold question: Can we stop T1D before it starts?
New Drug Aims to Retrain the Immune System in T1D
What if doctors could treat type 1 diabetes (T1D) by teaching the immune system to stop attacking cells in the pancreas? BRI researchers are working with the pharmaceutical company Novo Nordisk and global research consortium T1D TrialNet, testing a new approach that aims to do just that.
Is Hydroxychloroquine Safe for Autoimmune Diseases?
COVID-19 has put a therapy called hydroxychloroquine in the spotlight — and, at the same time, shrouded it in confusion.